Multi-objective de novo drug design with conditional graph generative model

Yibo Li, Liangren Zhang, Zhenming Liu

Journal of Cheminformatics · 2018 · 424 citations · 41 references

DOIFull text

Open access

Concepts

TL;DR

Deep generative models show promise for de novo molecule design, yet prior work has mainly used SMILES strings and existing graph models are too general and computationally expensive. The study proposes a new de novo molecular design framework using sequential graph generators that omit atom‑level recurrent units. The framework employs a conditional graph generative model that offers high flexibility for multi‑objective drug design. The method outperforms SMILES‑based models, scales to larger ChEMBL molecules, and successfully generates compounds meeting scaffold, drug‑likeness, synthetic accessibility, and dual‑inhibitor criteria.

Abstract

Recently, deep generative models have revealed itself as a promising way of performing de novo molecule design. However, previous research has focused mainly on generating SMILES strings instead of molecular graphs. Although available, current graph generative models are are often too general and computationally expensive. In this work, a new de novo molecular design framework is proposed based on a type of sequential graph generators that do not use atom level recurrent units. Compared with previous graph generative models, the proposed method is much more tuned for molecule generation and has been scaled up to cover significantly larger molecules in the ChEMBL database. It is shown that the graph-based model outperforms SMILES based models in a variety of metrics, especially in the rate of valid outputs. For the application of drug design tasks, conditional graph generative model is employed. This method offers highe flexibility and is suitable for generation based on multiple objectives. The results have demonstrated that this approach can be effectively applied to solve several drug design problems, including the generation of compounds containing a given scaffold, compounds with specific drug-likeness and synthetic accessibility requirements, as well as dual inhibitors against JNK3 and GSK-3β.

References

41